| ²é¿´: 1080 | »Ø¸´: 4 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
bobbyzwͳæ (³õÈëÎÄ̳)
|
[½»Á÷]
¡¾ÇóÖú¡¿Çë´ó¼Ò°ïæ·Ò뼸¸öҽѧ·½ÃæµÄ´Ê£¬Ð»Ð»£¡
|
||
|
ÎÒÕýÔÚ·Òëһƪ¹ØÓÚÖ×ÁöÒ©ÎïÁÙ´²ÊÔÑéµÄÎÄÕ£¬Óöµ½¼¸¸ö²»ºÃ·ÒëµÄ´Ê£¬¿ÒÇë¸ßÊÖÏàÖú£¬²»Éõ¸Ð¼¤£¡ 1.The NO16966 study also demonstrated significantly superior progression free survival£¨PFS£©in patients treated with XELOX and BV£¨XELOX£«BV£© than patients treated with XELOX. ÆäÖÐµÄ PFSÈçºÎ·Ò룿 2.¡¡included PFS based on tumor assessments reviewed by the Independent Review Committee £¨IRC£©and PFS on-treatment£¨based on tumor assessments up to 28 days after treatment in the primary study treatment phase£© ÆäÖеÄPFS on-treatment£¿ 3.Non-inferiority was also demonstrated for the XELOX/XELOX+P vs. FOLFOX-4/ FOLFOX-4+P comparison using the pre-specified arithmetic approach for the effect retention test£¨p<0.01006£©¡£ ÆäÖеÄeffect retention test µÄÈ·ÇÐ˵·¨£¿ 4.palmar-plantar erythrodysesthesia£¬ÕâÊÇÊÖ×ã×ÛºÏÖ¢µÄÁíÍâÒ»ÖÖ˵·¨£¬µ«²»ÖªÈçºÎ·Ò룿 лл£¡ [ Last edited by wfcicsd on 2007-6-16 at 16:06 ] |
» ²ÂÄãϲ»¶
321Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
¶«»ªÀí¹¤´óѧ»¯²Äרҵ26½ì˶ʿ²©Ê¿ÉêÇë
ÒѾÓÐ8È˻ظ´
288Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
¡¾¿¼Ñе÷¼Á¡¿»¯Ñ§×¨Òµ 281·Ö£¬Ò»Ö¾Ô¸ËÄ´¨´óѧ£¬³ÏÐÄÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ÄÜÔ´²ÄÁÏ»¯Ñ§¿ÎÌâ×éÕÐÊÕ˶ʿÑо¿Éú8-10Ãû
ÒѾÓÐ12È˻ظ´
0703»¯Ñ§µ÷¼Á
ÒѾÓÐ4È˻ظ´
ÕÐÊÕµ÷¼Á˶ʿ
ÒѾÓÐ10È˻ظ´
271²ÄÁϹ¤³ÌÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁÏר˶274Ò»Ö¾Ô¸ÉÂÎ÷ʦ·¶´óѧÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸Î人Àí¹¤²ÄÁϹ¤³Ìר˶µ÷¼Á
ÒѾÓÐ4È˻ظ´
2Â¥2007-06-16 16:08:53
hathq
ÈÙÓþ°æÖ÷ (ÕýʽдÊÖ)
No Cross, No Crown
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ¹ó±ö: 0.65
- ½ð±Ò: 4391
- ºì»¨: 4
- Ìû×Ó: 802
- ÔÚÏß: 93.4Сʱ
- ³æºÅ: 387682
- ×¢²á: 2007-05-30
- ÐÔ±ð: GG
- רҵ: ½ðÊô½á¹¹²ÄÁÏ
- ¹ÜϽ: ÍâÓïѧϰ

3Â¥2007-06-16 16:43:08
iamzane
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 129 (¸ßÖÐÉú)
- ¹ó±ö: 0.7
- ½ð±Ò: 24627.1
- É¢½ð: 40
- ºì»¨: 21
- Ìû×Ó: 1974
- ÔÚÏß: 459.5Сʱ
- ³æºÅ: 330866
- ×¢²á: 2007-03-24
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
|
progression free survival£¨PFS£©ÎÞ½øÕ¹´æ»î. palmar-plantar erythrodysesthesiaÒ»°ã¶¼·ÒëΪÊÖ×ã×ÛºÏÖ¢,Èç¹û·ÇÒª¾ßÌåÒ»µã,ÄǾÍÊÇÕÆ×ãºìÖ×ÌÛÍ´.palmar-plantar·Ö±ð±íÊ¾ÕÆºÍ×ã,¶øerythro-±íʾºìÉ«-dysesthesia±íʾ´¥Îï¸ÐÍ´. ÖÁÓÚPFS on-treatment±íʾÁ½ÖÖPFSÖеÄÒ»ÖÖ,Õâ¸öÒª¸ù¾ÝÉÏÏÂÎÄ×Ô¼º¹éÄÉÁË. ¶øeffect retention testºÃÏñûÓмûµ½ÕâÖÖ²âÊÔ.ÔÝʱֻÄܶ¨Îª×÷Óñ£³Ö²âÊÔ. ½ö¹©²Î¿¼. |
4Â¥2007-06-16 17:38:58
trixaypm
ľ³æ (Ö°Òµ×÷¼Ò)
¿ÝÌÙÀÏÊ÷»è³æ¼æÐ¡Ä¾³æÇå½à¹¤
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ¹ó±ö: 0.02
- ½ð±Ò: 4160.2
- ºì»¨: 3
- Ìû×Ó: 3522
- ÔÚÏß: 14.2Сʱ
- ³æºÅ: 238318
- ×¢²á: 2006-04-05
- ÐÔ±ð: GG
- רҵ: ¸ß·Ö×ÓÎïÀíÓë¸ß·Ö×ÓÎïÀí»¯
¡ï
iamzane(½ð±Ò+1):ллÄãµÄ»ý¼«°ïÖú!
iamzane(½ð±Ò+1):ллÄãµÄ»ý¼«°ïÖú!
|
1.progression free survival£¨PFS£©ÊÇÎÞ½øÕ¹Éú´æÊ±¼ä(ÂÊ)µÄÒâ˼!! 2.ÎÒÒ²²»»á. 3. effect retention testÓ¦¸ÃÊÇЧ¹û±£³Ö²âÊÔ°É 4.Palmar-plantar erythrodysesthesiaÓ¦ÒëΪ: ÕÆ×ãºìÖ×ÌÛÍ´ ÏñÕâÖÖÎÊÌâ,ÄãÄõ½Óн±ÎÊ´ð°æÀïÈ¥,Ò»Á½¸ö½ð±Ò¾ÍÓкܶàÈ˸øÄã·Òë. |
5Â¥2007-06-16 17:47:03













»Ø¸´´ËÂ¥